ALOX15B and breast carcinoma: 15-LOX-1 and 15-LOX-2 are suggested to have tumour-suppressor roles in breast cancer, as their expression is reduced in malignant breast cells and tissues compared with healthy ones, whereas the expression of 5-LOXAP is increased in breast cancer and together with 12-LOX also associated with poor survival of the patient [3].